‘Like Christmas’: woman’s relief after test finds she can skip chemotherapy

A landmark international trial, the Optima study, has demonstrated that a genomic test called Prosigna can accurately identify breast cancer patients who can safely forgo chemotherapy without compromising survival rates. Participant Karen Bonham, who avoided chemotherapy based on the test results, remains cancer-free nine years later, highlighting the potential for this technology to improve quality of life for millions of patients.